This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Esbriet® (pirfenidone) Benefit Granted By German Federal Joint Committee (G-BA)

Stocks in this article: ITMN

BERLIN, March 15, 2012 /PRNewswire/ -- InterMune, Inc. (NADSAQ: ITMN) today reported that Germany's Federal Joint Committee (G-BA) has announced its decision granting the additional benefit of Esbriet® (pirfenidone) in adults for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  Esbriet's additional benefit was classified as stage 4 (not quantifiable benefit)  in the rating system established under Germany's AMNOG pharmaceutical law.  A non-quantifiable benefit means that the drug has an additional benefit, which will be defined in the future via experience in daily clinical use or clinical studies.  Based on this, a stage of 1-3 will be assigned.  G-BA is the highest decision-making body of the self-governing healthcare system in Germany.

Today's final assessment of Esbriet's added benefit by the G-BA is improved from the preliminary assessment of the benefits of Esbriet issued by the Institute for Quality and Efficiency in Healthcare (IQWiG) in December 2011.  In its preliminary assessment, IQWiG did not determine an additional benefit of Esbriet.

"We are pleased that the G-BA has recognized the additional benefit of Esbriet for patients with IPF," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune.  "Esbriet is the first orphan drug to be evaluated under the new German system for assessing the additional benefit to patients of a new medicine.  As the only therapy approved for IPF, G-BA determined that there is no appropriate comparator treatment to Esbriet.  Today's decision applies to all adult patients with mild-to-moderate IPF and ensures continued reimbursement in Germany for the first drug shown to be efficacious, safe and generally well-tolerated in this relentless and uniformly fatal disease."

Dr. Markus Leyck Dieken, InterMune's Senior Vice President and Country Manager for Germany, said, "We appreciate the input of those who helped to inform G-BA in making its decision, including patients, physicians, the pharmaceutical association and the German pulmonology society.  We believe their comments were constructive in helping G-BA to arrive at today's final and positive assessment, and we thank them for their contributions on behalf of IPF patients."

InterMune's next step is to enter price negotiations with the Statutory Health Insurance, the umbrella organization which represents Germany's sickness funds.  Sickness funds are the health insurance providers that reimburse the cost of pharmaceutical products in Germany.

Under Germany's AMNOG law, the price charged by a manufacturer for a new pharmaceutical product is reviewed during the 12 months following the medicine's launch.  The current price for Esbriet in Germany will remain in effect until the pricing review is completed, which is expected by September 15, 2012.

Esbriet ® (pirfenidone) Demonstrates Benefit for Patients

In its written and oral comments to G-BA during the review process, InterMune noted that pirfenidone slows both disease progression and the decline of physical performance.  Compared to placebo, the results of a pooled analysis of pivotal trials showed that pirfenidone achieved a 31% relative reduction in the decrease in walking distance from the 6-minute walk test (6MWT) (p<0.001).  In addition, a pooled analysis showed that pirfenidone significantly reduced the relative decrease in percent predicted forced vital capacity (FVC) by approximately 23%, compared to placebo (p=0.005).  Considering the poor prognosis of IPF, the reversible side effects of pirfenidone are viewed as acceptable. 

Conference Call and Webcast Details

InterMune will host a live webcast of a conference call today at 4:00 p.m. EDT to discuss the G-BA's final assessment of Esbriet's additional benefit.  Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21582928.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID# 21582928.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs